Trillium Therapeutics (TRIL) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) from a buy rating to a hold rating in a research report report published on Saturday, January 20th. Zacks Investment Research currently has $8.75 price objective on the biotechnology company’s stock.

According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “

Several other research analysts also recently commented on the stock. HC Wainwright reaffirmed a buy rating and issued a $10.00 target price on shares of Trillium Therapeutics in a research note on Thursday, December 14th. ValuEngine downgraded shares of Trillium Therapeutics from a hold rating to a sell rating in a research note on Friday, December 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $12.25.

Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at $7.35 on Friday. The firm has a market cap of $77.18, a P/E ratio of -2.86 and a beta of 12.50. Trillium Therapeutics has a one year low of $4.15 and a one year high of $13.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings results on Friday, November 10th. The biotechnology company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.02. equities analysts anticipate that Trillium Therapeutics will post -3.69 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Trillium Therapeutics during the 4th quarter valued at $144,000. Citadel Advisors LLC purchased a new position in shares of Trillium Therapeutics in the 4th quarter worth about $180,000. Wells Fargo & Company MN raised its position in shares of Trillium Therapeutics by 57.7% in the 4th quarter. Wells Fargo & Company MN now owns 26,100 shares of the biotechnology company’s stock worth $189,000 after purchasing an additional 9,550 shares during the last quarter. Virtu KCG Holdings LLC purchased a new position in shares of Trillium Therapeutics in the 2nd quarter worth about $128,000. Finally, K2 Principal Fund L.P. purchased a new position in shares of Trillium Therapeutics in the 2nd quarter worth about $264,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://ledgergazette.com/2018/02/13/trillium-therapeutics-tril-downgraded-to-hold-at-zacks-investment-research.html.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply